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Abstract
Background: Mesenchymal stem cells (MSCs) show therapeutic efficacy in many different age-related degenerative
diseases, including Alzheimer’s disease. Very little is currently known about whether or not aging impacts the
transplantation efficiency of MSCs.
Methods: In this study, we investigated the distribution of intravenously transplanted syngeneic MSCs derived from
young and aged mice into young, aged, and transgenic APP/PS1 Alzheimer’s disease mice. MSCs from male donors
were transplanted into female mice and their distribution pattern was monitored by PCR using Y-chromosome
specific probes. Biodistribution of transplanted MSCs in the brains of APP/PS1 mice was additionally confirmed by
immunofluorescence and confocal microscopy.
Results: Four weeks after transplantation into young mice, young MSCs were found in the lung, axillary lymph
nodes, blood, kidney, bone marrow, spleen, liver, heart, and brain cortex. In contrast, young MSCs that were
transplanted into aged mice were only found in the brain cortex. In both young and aged mouse recipients,
transplantation of aged MSCs showed biodistribution only in the blood and spleen. Although young transplanted
MSCs only showed neuronal distribution in the brain cortex in young mice, they exhibited a wide neuronal
distribution pattern in the brains of APP/PS1 mice and were found in the cortex, cerebellum, hippocampus,
olfactory bulb, and brainstem. The immunofluorescent signal of both transplanted MSCs and resident microglia was
robust in the brains of APP/PS1 mice. Monocyte chemoattractant-1 levels were lowest in the brain cortex of young
mice and were significantly increased in APP/PS1 mice. Within the hippocampus, monocyte chemoattractant-1
levels were significantly higher in aged mice compared with younger and APP/PS1 mice.
Conclusions: We demonstrate in vivo that MSC biodistribution post transplantation is detrimentally affected by
aging and neuronal health. Aging of both the recipient and the donor MSCs used attenuates transplantation
efficiency. Clinically, our data would suggest that aged MSCs should not be used for transplantation and that
transplantation of MSCs into aged patients will be less efficacious.
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Background
Mesenchymal stem cells (MSCs) are a heterogenic mix of
progenitor and stem cells that can differentiate into vari-
ous mesenchymal tissues, including cartilage, bone, and
adipose tissue [1]. Transplantation of MSCs has been
investigated for a variety of diseases and many of these
approaches have already entered clinical trials [2]. MSCs
are often administered systemically for clinical application
and systemic delivery of MSCs has been performed for a
variety of ailments, including osteogenesis imperfecta [3],
bone defects [4], diabetes [5], myocardial infarctions [6],
multiple sclerosis [7], and arthritis [8]. The underlying re-
generative mechanism of action seems to be related to the
immune-modulatory, anti-inflammatory, and anti-fibrotic
activity of MSCs [9, 10].
The success of a given MSC transplantation therapy
may depend on a variety of factors, such as whether or
not they were pre-incubated with protective compounds
[11, 12] or under specific environmental conditions [13].
Another key factor underlying MSC transplantation effi-
ciency may be the ability of MSCs to localize, or migrate,
into target tissues of interest [14]. Intravenously trans-
planted MSCs have been found in very low frequencies in
different organs using various labelling and tracking
methods, including fluorescently labelled cells, xenogeneic
transplantation, and sex-linked chromosome detection
tracked by PCR [15–19]. Twenty-four hours after intra-
venous transplantation, MSCs are mostly found in the
lung, liver, kidney, skin, thymus, lymph node, and gut with
1–2.7% of transplanted cells homing to these different or-
gans in young animals [20]. MSCs first accumulate in the
lung 24–48 hours after transplantation but can be found
later in the liver, kidney, spleen, and other organs, particu-
larly those showing injury [21]. Multimodal MRI nanopar-
ticles with enhanced near-infrared fluorescence have been
used recently to perform in-vivo imaging of human
adipose-derived stem cells in an Alzheimer’s disease
mouse model [22]. Cells administered via tail-vein
injection were observed in the tail, body, and brain of
Alzheimer’s disease mice up to 10 days after transplant-
ation (with the strongest signal at day 3), but not in the
brains of wild-type (WT) controls [22]. Post-mortem
examination of organs revealed weak fluorescent signals
in WT brain tissue, suggesting that some cells are able to
cross the blood–brain barrier (BBB) in young animals.
However, the strongest signals were observed in the
Alzheimer’s disease mouse brains, which the authors attri-
bute to leakage of the BBB brought about as a result of
neurological disease. In addition, human adipose-derived
stem cells had transmigrated to the gastrointestinal tract,
kidney, liver, and bladder of all injected mice [22].
MSCs mediate numerous therapeutic effects by pro-
moting repair directly via differentiation into critical cell
types or indirectly through the secretion of substances
and the activation of endogenous mechanisms [23]. In
order to mediate such beneficial effects, MSCs must first
home or migrate to a specific site of injury or damage.
MSC migration is therefore thought to play a paramount
role in the remedial process [23]. Migration of MSCs is
subject to extensive regulation [13, 23, 24] and existing
evidence suggests that MSCs migrate to specific organs
in a manner similar to leukocytes. They adhere to endo-
thelial cells in the vascular system and transmigrate
across the vascular endothelium [25] towards injured
and inflamed tissues [26, 27]. MSCs home to areas of
injury along a chemokine gradient and several chemo-
kines have been identified which affect MSC migration,
including stromal cell derived factor 1 alpha, CXC
chemokine receptor type 4, transforming growth factor
beta 1, interleukin 1 beta, and tumour necrosis factor
alpha [24, 28, 29]. Many of these specific regulatory
factors have been shown to also affect the expression of
chemokines and selectins in MSCs [13, 30–32].
Although conflicting reports exist in the literature as to
whether or not MSC migration is affected by aging [13, 33],
aging is known to detrimentally affect MSC functionality
[1]. More broadly, aging is known to exert negative effects
on stem cells and progenitor cells [34–36]. Aging increases
the susceptibility of MSCs to damaging agents like reactive
oxygen species, disrupts cell population dynamics, dimin-
ishes therapeutic efficacy, and mediates other harmful
effects [1, 37–39]. While numerous studies have uncovered
aspects of MSC aging, it remains to be determined whether
or not aging affects MSC transplantation efficiency. More-
over, further data are required to clarify whether or not
MSC migration and engraftment is affected in vivo by
aging. To better elucidate these questions, we assessed
MSC biodistribution in vivo in various mouse organs
following transplantation with young or old MSCs into
young, old, or diseased animals.
Methods
Animals
C57Bl/6 mice as a source for bone marrow were obtained
from the University of Leipzig or Charles River. The GFP
transgenic mice were from the Paul Flechsig Institute for
Brain Research, University of Leipzig, and the transgenic
mice overexpressing human amyloid precursor protein
(APPKM670/671NL) and presenilin-1 (PS1L166P) under Thy-1
promoter control were obtained from University of
Leipzig (Prof. Bechmann).
MSC preparation
After isolation, bone marrow from tibiae and femurae
were harvested as described previously [40] and cultured
in DMEM 1×, low glucose (Gibco) with GlutamaxI
(Gibco), 10% fetal calf serum (Biochrome), and 1% peni-
cillin/streptomycin (Gibco) for the isolation of adherent
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MSCs. Briefly, mouse bone marrow cells were obtained
by centrifugation from tibiae and femurae and were cul-
tured according to the method of Dobson et al. [41].
MSCs were isolated by the method of Sekiya et al. [42].
MSCs were passaged when they were at 70% confluency
using trypsin (0.25% trypsin–EDTA; Gibco). Like we
have done previously [43], fluorescence-activated cell
sorting was used to confirm the identity of MSCs by
assessing specific markers (e.g., CD11b–, CD45–, CD44+,
CD90+). Similarly to earlier studies [1, 13, 43], mesoder-
mal lineage differentiation was also performed to con-
firm successful MSC isolation and culturing.
MSC transplantation
To set up a sex-mismatched transplantation, 1 × 106
MSCs (passages 2–3) from male donors were transplanted
into female recipients by tail-vein injection. MSCs were
isolated either from young mice (2–3 months old) or from
aged mice (12–13 months old). Recipient mice were either
young (3 months old) or old (13–21 months old). Older
APP/PS1 mice (12–15 months old) also received young
MSCs. Twenty-eight days after transplantation, the mice
were sacrificed and the organs isolated for analysis. Three
to five mice were used for each experimental group. Three
male mice were also transplanted with 1 × 106 bone-
marrow derived MSCs from female GFP-transgenic mice
(3 months old) and were sacrificed for histological analysis
28 days after transplantation.
Preparation of tissue
For genomic DNA (gDNA) isolation, mice were sacrificed
28 days after transplantation and transcardially perfused
with 0.9% NaCl. Peripheral organs (lung liver, kidney, heart,
lymph nodes, bone marrow, spleen) were removed, as well
as the brain which was divided into five regions (hippocam-
pus, cortex, cerebellum, brainstem, olfactory bulb). The tis-
sue was mechanically homogenized in peqGOLD TriFast™
(PeqLab) and stored at –80 °C until further use.
For histology, mice were sacrificed after 28 days and per-
fused transcardially with 0.9% NaCl followed by 4% parafor-
maldehyde and 0.1% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.4). Brains were removed and immersion-fixed
overnight in the same fixative at 4 °C. Brains were cryopro-
tected in 30% sucrose in 0.1 M phosphate buffer (pH 7.4)
with 0.1% sodium azide, cut into 40 μm slices with a cryo-
microtome in the frontal plane, and collected in 0.1 M
phosphate buffer (pH 7.4) with 0.1% sodium azide.
gDNA isolation
gDNA was isolated using peqGOLD TriFast™ (PeqLab)
according to the manufacturer’s instructions. After isola-
tion, gDNA was fractionated through an injection needle
(size 2; Braun) using a 0.01–1 ml syringe (Braun). gDNA
was then either further purified using a gDNA clean-up
kit (Macherey-Nagel) or purified and enriched using a
gDNA clean-up XS kit (Macherey-Nagel). All kits were
used according to the manufacturer’s instructions.
RNA isolation and quantitative RT–PCR
RNA was extracted from organs using peqGOLDTrifast™
reagent according to the manufacturer’s instructions (30-
2040; PeqLab) and treated with DNaseI (EN0521; Life Tech-
nologies). This was followed by cDNA synthesis using Super-
scriptIII reverse transcriptase (18080085; Life Technologies)
and Oligo (dT)18-Primers (SO132; Thermo Scientific) at 50 °
C for 1 hour. cDNA was used as PCR template in a 1:10 dilu-
tion and each sample run in triplicate. Quantitative PCR was
performed using Express SYBR GreenER qPCR Supermix
Universal (1178401 K; Life Technologies), additional 1× Sybr-
Green (S-7567; Life Technologies), and 0.2 μM primer each
on the DNA engine Opticon2 (Biorad) (see Table 1) with the
following cycle conditions: primary denaturation at 95 °C for
3 min, 35 cycles for 30 s at 95 °C, 30 s at 60 °C, and 30 s at
72 °C, followed by fluorescence measurement. Absolute
quantification was performed for every single gene with three
technical repeats per sample. Serial dilutions of plasmid
controls with known molecule concentrations were used as
positive control and to generate standard curves for the PCR.
Expression of target genes was normalized using 36B4 (large
ribosomal protein P0, RPLP0) as a reference gene.
Cell-tracking PCR
Male gDNA was tracked by PCR using Y-chromosome spe-
cific primers (5′-CATGGAGAGCCACAAGCTAACCA-3′
and 5′-GTCCCAGCATGAGAAAGATTCTTCC-3′). Up
to four copies of Y-chromosomes can be detected in the
background of up to 50 ng gDNA. The PCR mix contained
0.2 μM primers, 0.2 mM dNTPs (Thermo Scientific),
2.8 mM MgCl2 (Life Technologies), 1× buffer without
MgCl2 (Life Technologies), and 1 U platinum taq polymer-
ase (Life Technologies). gDNA (5 μl) was added to the mix
as a template. As a positive control, 5 μl gDNA isolated
from male mouse brain tissue was used (concentration:
0.55 ng/ml in TE buffer, pH 8.0) instead of the sample
gDNA. The single copy gene 36B4 (5′-CCGTGTGAGGT-
CACTGTGCCAGCTC-3′ and 5′-GCCCAAAGCCTGGA
AGAAGGAGGTC-3′) was used as reference gene. PCR
Table 1 PCR primers
Name Gene Sense primer
(5'–3')
Antisense primer
(5'–3')
NCBI accession
number
36B4 Ribosomal
protein
large P0,
RPLP0
CCGTGTGAG
GTCACTGTG
CCAGCTC
GCCCAAAGC
CTGGAAGA
AGGAGGTC
NM_007475.5
MCP-1 Transcription
regulatory
protein
MCP-1 (POU 1)
GCAGTAATC
CTCACCAGC
CCAACGC
GATCCCGTC
CTCATCCAG
ACTTGG
L13763.1
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was performed in a thermocycler T professional (Biometra)
with a primary 3-min denaturation step at 95 °C followed
by 35 cycles: 30 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C,
with a final 3-min elongation step at 72 °C. The PCR prod-
ucts were verified by agarose gel electrophoresis.
Immunohistochemistry
Immunohistochemistry was performed with free-floating
sections. Brain slices were washed once with PBS containing
0.05% Tween20 (PBS-T) (P2287-100ML; Sigma-Aldrich)
and treated with 60% methanol (VWR Prolabo) for 1 hour.
Sections were incubated in blocking solution consisting of
PBS-T plus 2% bovine serum albumin (11930; Serva), 0.3%
milk powder (T145; Roth), and 0.5% donkey normal serum
(017-000-001; Jackson Immuno Research) for 30 min prior
to incubation with the primary antibody. Immunofluores-
cence staining for microglia was performed with rabbit anti-
Iba-1 (1:500; WAKO) in blocking solution overnight at 4 °C,
followed by secondary antibody donkey-anti-rabbit Cy3
(1:250, 711-165-152; Dianova) for 1 hour. Finally, slices were
washed three times and incubated for 10 min with DAPI
(1:10,000; Sigma) at 4 °C and washed once. For immigrated
GFP+ MSCs, no immunohistochemical enhancement was
used. Slices were mounted on glass slides, dried, and cover-
slipped with entellan in toluol (108323; Merck).
Microscopy and image processing
Tissue sections were examined with the Keyence BZ-9000
microscope (Keyence Corporation, USA). Fluorescence
labelling was examined with a Zeiss confocal laser scan-
ning microscope (LSM 510; Zeiss, Jena, Germany). For
imaging of GFP (green fluorescence), an argon laser with
488-nm excitation was used and emission from Cy2 was
recorded at 510 nm with a low-range band pass filter
(505–550 nm). For secondary Cy3-labelling (red fluores-
cence), a helium–neon laser with 543-nm excitation was
used and emission from Cy3 at 570 nm was detected ap-
plying a high-range band pass (560–615 nm). For DAPI
labelling, a 405-nm diode laser was used. Photoshop CS2
(Adobe Systems, Mountain View, CA, USA) was used to
process the images with minimal alterations to the bright-
ness, sharpness, colour saturation, and contrast.
Statistical analysis
Data are presented as the mean of the samples and standard
deviation as the standard error of the mean (SEM). Statis-
tical analysis was performed using SigmaPlot 11.0 software
(Systat Software Inc.) using one-way ANOVA. p < 0.05 was
considered statistically significant.
Results
Post-transplantation health and MSC phenotyping
None of the mice receiving MSCs died or showed any
pathological changes post transplantation. All MSCs used
for transplantation were at culture passages 2–3 and
exhibited tri-lineage differentiation potential into adipo-
cytes, chondrocytes, and osteocytes (Additional file 1:
Figure S1). MSCs transplanted were positive for CD29,
CD44, CD73, CD105, and CD106 and were negative for
CD45 and CD11 (Additional files 2 and 3: Figure S2 and S3).
Biodistribution of systemically transplanted young MSCs
into young and old mice
MSCs from young male donors were transplanted into
young and old female recipients via tail-vein injection.
As described in the Methods, Y-chromosome PCR ana-
lysis was then performed to assess the biodistribution of
MSCs in isolated organs and tissues post mortem.
Following a tail-vein injection, young transplanted MSCs
were found in the lung, axillary lymph nodes, blood, kid-
ney, bone marrow, spleen, liver, heart, and brain cortex
of young mice (Fig. 1a). In contrast, male gDNA was
only present in the brain cortex of old mice following
transplantation with young MSCs (Fig. 1a).
Biodistribution of systemically transplanted old MSCs into
young and old mice
When aged MSCs were transplanted into young or aged
mice, transplanted MSCs were only found in the blood
and spleen (Fig. 1b). Although more MSCs were found
in the spleen of young recipient mice, more MSCs were
present in the blood of aged recipient mice (Fig. 1b).
When young MSCs were transplanted into young and
old mice, biodistribution in the brain was exclusive to
the cortex (Fig. 1a). Conversely, aged MSCs were not
found in any neuronal tissue post transplantation into
either young or old mice (Fig. 1b). In comparison with
young MSCs transplanted into young mice (Fig. 1a),
aged MSCs transplanted into young mice showed a
markedly decreased biodistribution (Fig. 1b).
Biodistribution of systemically transplanted young MSCs
into old APP/PS1 mice
In C57Bl/6 recipients, transplanted young MSCs showed
neuronal distribution in the brain cortex (Fig. 1a) while
transplanted old MSCs were not found in any brain
tissues (Fig. 1b). In contrast, young MSCs which were
transplanted into aged APP/PS1 mice were predominantly
found in neuronal tissues. In addition to being distributed
in the lung, bone marrow, and kidney, transplanted MSCs
in these mice were found in all isolated brain parts,
including the cortex, cerebellum, hippocampus, olfactory
bulb, and brainstem (Fig. 1c). The strongest signals were
found in the hippocampus and brainstem. APP/PS1 mice
represent a mouse model of Alzheimer’s disease and, in
this murine model of neuronal degeneration, MSCs
transplanted via tail-vein injections homed preferentially
into the brain.
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To further confirm that MSCs were indeed homing to the
brain following a tail-vein injection, we employed immuno-
fluorescence staining in addition to our Y-chromosome PCR
analysis. GFP+ MSCs from young GFP-positive mice were
transplanted into aged APP/PS1 mice via tail-vein injection.
Immunofluorescent staining for nuclei (DAPI) and Iba-1, a
marker of microglia [44], was then performed on frontal
sections. In correspondence with the Y-chromosome PCR
results, immigrated GFP+ MSCs were found in all brain
regions, especially in the cortex and hippocampus. GFP+
MSCs appeared strongly attracted to inflammation sites and
seemed to be integrated into the network of resident micro-
glia (Fig. 2). A representative, low-magnification image is
also included to highlight the reliability of this staining pat-
tern (Additional file 4: Figure S4).
Expression of monocyte chemoattractant protein-1 in
young, aged, and APP/PS1 mouse brains
Monocyte chemoattractant protein-1 (MCP-1) is known
to regulate the function and behaviour of MSCs [45, 46].
Using PCR, we measuredMCP-1 gene levels in the hippo-
campus and cortex of young, aged, and APP/PS1 mice
(Fig. 3). We found that, in the hippocampus, MPC-1 levels
were significantly higher (p < 0.001) in aged mice com-
pared with MCP-1 levels in young and APP/PS1 mice
(Fig. 3a). In the cortex, MCP-1 expression was the lowest
in young mice (Fig. 3b). MCP-1 expression was highest in
APP/PS1 mice and was significantly greater (p < 0.001)
than MCP-1 expression in both young and aged mice
(Fig. 3b).
Biodistribution overview
The results from the biodistribution experiments are
summarized visually in Fig. 4. It is especially lucid that
aging impacts transplantation efficiency when the data
are presented in this tabular manner, because no young
transplanted MSCs were found to home in any organ ex-
cept the brain in any of the four aged mice tested (Fig. 4).
Conversely, young MSCs were found in at least one
organ in every young mouse recipient. Additionally, the
overall engraftment was clearly lower in MSCs from
aged donors compared with MSCs from young donors
(Fig. 4). That MSCs migrated to various regions of the
brain (young MSCs to the cortex of young and aged
mice, and young MSCs to the cortex, cerebellum,
Fig. 1 Biodistribution of young and old MSCs transplanted into young, old, and APP/PS1 mice. MSCs derived from young or old male mice were
transplanted into young, old, and Alzheimer’s disease female mice via tail-vein injections. Percentage of male gDNA in organs was assessed and quantified
28 days after transplantation. (a) Young MSCs were intravenously transplanted into either young (n= 3) or old (n= 4) recipient mice. Young MSCs were
found in the lungs, axillary lymph nodes, blood, kidney, bone marrow, spleen, liver, heart, and brain cortex of mice. In contrast, young MSCs were only
found in the brain cortex of old mice. (b) Aged MSCs were transplanted into young (n= 3) and old (n= 5) mice. Biodistribution of aged MSCs was exclusive
to the blood and spleen. (c) Young MSCs were injected into the tail veins of APP/PS1 Alzheimer’s disease (AD) mice (n= 5). Biodistribution was found in
the cortex, cerebellum, hippocampus, olfactory bulb, brain stem, liver, bone marrow, and lung. gDNA genomic DNA, MSC mesenchymal stem cell
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hippocampus, olfactory bulb, and brain stem of APP/
PS1 mice) is also very apparent (Fig. 4).
Discussion
In our previous work, we demonstrated that aging detri-
mentally affects intravenously or intranasally transplanted
in-vitro differentiated microglia derived from mouse bone
marrow [47]. Specifically, we showed that transplanted
microglia from young donors migrated to the brain in
both young and old recipients while transplanted micro-
glia from older donors failed to exhibit migration into the
brain [47]. In the present work, we corroborate and
expand upon this prior work [47] by presenting evidence
that aging substantially hinders the transplantation
efficiency of MSCs.
Although young MSCs migrated to nine organs when
transplanted into young mice, young MSCs only mi-
grated into a single organ in old mice. This result dem-
onstrates that, even when young, robust MSCs are used
for transplantation, the age of the recipient drastically af-
fects transplantation efficiency and post-transplantation
migration. Aspects of senescence in the elderly recipi-
ents must therefore be preventing the efficient migration
or survival of MSCs. We recently showed that cytokines,
growth factors, and O2 concentration affect MSC
migration [13]. These and other age-dependent regula-
tory factors [35, 48] are probably anomalous in elderly
mice and this dysregulation might be responsible for the
restricted immigration of MSCs into the brain.
We further investigated how effectively intravenously
transplanted aged MSCs would distribute in both young
Fig. 2 Migration of transplanted MSCs into the brain of APP/PS1 mice. Intravenously transplanted GFP + MSCs were able to migrate into the
brain parenchyma. GFP+ MSCs (green, centre panel) were found in association with activated microglia (Iba-1; red, left panel), but only partly
showing overlap with Iba-1 immunoreactivity (right panel). In the merged image (orthoview based on stack analysis), Iba-1 and GFP are shown in
combination with nuclei (DAPI, blue) and, in addition to the X–Y image, orthogonal X–Z and Y–Z projections are shown. Scale bar: 20 μM
(Colour figure online)
Fig. 3 Monocyte chemoattractant protein-1 (MCP-1) levels in the hippocampus and cortex of young, aged, and APP/PS1 mice. Using PCR, the levels of
the chemokine and MSC regulator MCP-1 were quantified in the hippocampus and cortex of young, aged, and APP/PS1 mice without cell treatment.
a Compared with young and APP/PS1 mice, MCP-1 levels were significantly increased in the hippocampus of old mice. b Within the brain cortex,
young mice showed the lowest levels of MCP-1 expression. Compared with both young and old mice, MCP-1 levels were significantly increased in the
brain cortex of APP/PS1 mice. ***p < 0.001
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and old mice. Consistent with our findings regarding
transplantation efficiency of young MSCs into aged
mice, we found that aged MSCs revealed a dramatically
reduced biodistribution in both young and aged recipi-
ents and were only found in two tissues—the blood and
the spleen. Here, more young MSCs were found in the
spleen of old mice and more old MSCs were found in
the blood of old mice. We postulate that young MSCs
were more capable of migrating into the spleen tissue
while older MSCs were less able to leave the blood and
home into this organ. Because this difference was not
statistically significant, more research is required to de-
termine whether this disparity is invariable.
These data indicate that, in addition to the age of the
recipient host affecting MSC biodistribution, the age of
the used MSCs themselves affects distribution into various
tissues. Aging has been reported previously to detrimen-
tally affect the ability of MSCs to mediate wound healing
and vascular support [37]. Moreover, work by Bustos et al.
[33] suggests that aging may impair the migratory and
anti-inflammatory abilities of MSCs. Our data substantiate
these and other claims that aging detrimentally affects
MSC functionally. We add novel in-vivo data showing that
the deleterious effects of aging significantly attenuate
MSC biodistribution post transplantation.
Unlike aged C57Bl/6 mice, aged APP/PS1 mice showed a
broad biodistribution following transplantation with young
MSCs, with a preferential attraction towards the brain.
Young MSCs were found in each of the examined brain
areas (cortex, cerebellum, hippocampus, olfactory bulb,
brainstem) following transplantation. Because some contro-
versy still exists on whether or not MSCs can cross the
BBB [49], we verified biodistribution in the brain by both Y-
chromosome PCR and immunofluorescence detection of
GFP+ MSCs. Our mice were not irradiated and not
immune suppressed, which confirms that MSCs can cross
the BBB in untreated, young, and aged mice. Concerning
the APP/PS1 mice, the BBB is known to be affected in
Fig. 4 Biodistribution overview. Tabular biodistribution summary for each of the mice used for the transplantation experiments. AD Alzheimer’s
disease, MSC mesenchymal stem cell
Fabian et al. Stem Cell Research & Therapy  (2017) 8:85 Page 7 of 10
neurodegenerative disorders like Alzheimer’s disease. BBB
breakdown due to disrupted tight junctions, altered trans-
port processes, and inflammatory effects have been re-
ported to underlie neurodegenerative diseases [50]. These
factors would make it notably easier for MSCs to infiltrate
the brain.
The preferential biodistribution in the brain of recipient
APP/PS1 mice compared with recipient young and aged
C57Bl/6 mice might also be in part due to differences in
MCP-1 levels. In the brain cortex, APP/PS1 mice showed
significantly higher MCP-1 levels compared with old and
young mice. Because MCP-1 is known to stimulate MSC
migration [51], this increased MCP-1 signal in the brain
cortex of APP/PS1 mice might be a factor that attracts
more MSCs into the brain. A confounding factor that does
not support this hypothesis is that, although MCP-1 levels
were also increased in older mice compared with young
mice, older mice recipients showed a significantly reduced
biodistribution. It is important to note, however, that this
difference in MCP-1 levels between older and younger
mice was not statistically significant.
Another paradoxical factor is that, in the mouse
hippocampus, MCP-1 levels were lowest in APP/PS1
mice and highest in aged mice. Aged mice exhibited
significantly higher MCP-1 levels than both young and
APP/PS1 mice. One possible explanation for this is that
amyloid plaques in this Alzheimer’s disease mouse
model are more abundant in the cortex than in the
hippocampus [52], which could explain why MCP-1
levels were significantly increased in the brain cortex
but not in the hippocampus of APP/PS1 mice.
Amyloid-β can activate microglia, which in turn has
been reported to increase MCP-1 production in rodents
and humans [53]. Another possibility is that MCP-1
levels do not discernibly affect biodistribution and that
the primary factor increasing neuronal distribution in
APP/PS1 is disruption of the BBB due to neurodegener-
ation. Follow-up research is required to understand the
detailed mechanisms underlying the observed differ-
ences in biodistribution between young, old, and APP/
PS1 mice.
Conclusions
In sum, we demonstrate in vivo that MSC biodistri-
bution post transplantation is detrimentally affected
by aging and neuronal health. Aging of both the
recipient and the donor MSCs used attenuates
transplantation efficiency. Clinically, our data would
suggest that aged MSCs should not be used for trans-
plantation and that transplantation of MSCs into aged
patients will be less efficacious. Further studies are
warranted to identify novel therapeutic strategies to
improve biodistribution of MSCs in aged hosts.
Additional studies are also warranted to see whether
aging affects post-transplantation biodistribution in
other disease models and to determine whether young
and old MSCs preferentially home to organs of inter-
est in aged versus young animals.
Additional files
Additional file 1: Figure S1. showing mesodermal lineage
differentiation of bone-marrow-derived MSCs. Bone-marrow-derived
MSCs were differentiated in vitro under adipogenic (a), osteogenic (b),
or chondrogenic (c) conditions. Verification of the differentiation was
done by qualitative analysis: adipogenesis shown by staining lipid vesicles
with Oil red-O (a), osteogenesis shown by staining alkaline phosphatase
with Fast Red (b), and chondrogenesis shown by staining sulphated
proteoglycans typical for extracellular matrix composition with Alcian
Blue under acidic conditions.
Additional file 2: Figure S2. showing cell marker panels of Sca1, CD73,
CD105, CD29, and CD45 in bone-marrow derived MSCs. A cell marker panel
was performed via FACS on Bl6, bone-marrow-derived MSCs at passage 3.
P2-Q4 represents the negative quadrant in the bottom left (purple). P2-Q1
represents the positive quadrant in the upper left (green). (TIF 1142 kb)
Additional file 3: Figure S3. showing cell marker panels of CD11b,
CD106, and CD44 in bone-marrow-derived MSCs. A cell marker panel was
performed via FACS on Bl6, bone-marrow-derived MSCs at passage 3.
P2-Q4 represents the negative quadrant in the bottom left (purple). P2-Q1
represents the positive quadrant in the upper left (green). Bar graph
(bottom right) and textual table (bottom left) included to summarize the
overall results of the FACS experiments. (TIF 831 kb)
Additional file 4: Figure S4. showing a low-magnification image of trans-
planted MSCs in the brain of APP/PS1 mice. Representative low-magnification
image showing the migration of transplanted GFP-positive MSCs (green) into
the brains of APP/PS1 mice. GFP-expressing MSCs were found in association
with activated microglia (Iba-1, red). Sections were stained with DAPI to
highlight nuclei as a positional marker. Scale bar: 50 μM. (TIF 4445 kb)
Abbreviations
BBB: Blood–brain barrier; MCP-1: Monocyte chemoattractant protein-1;
MSC: Mesenchymal stem cell; WT: Wild type
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